Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
Grogan, Martha , López-Jiménez, Francisco , Guthrie, Spencer , Kumar, Nisith, Langevin, R.Eugene, Lousada, Isabelle , Witteles, Ronald , Royyuru, Ajay K. , Rosenzweig, Michael , Cairns‐Smith, Sarah , Royyuru, Ajay , Ouyang, David , Lopez-Jimenez, Francisco , Kumar, Nisith, Langevin, Reuben

Mayo Clinic

Journal of the American Heart Association | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/jaha.124.036533 | PMID 40207501 Get It

Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This narrative review of published literature describes the performance of AI tools that use data from ECGs and echocardiography to improve identification of CA and challenges that hinder adoption of these tools. Thirteen studies met inclusion criteria with sample sizes ranging from 50 to 2451 patients. Four studies used ECG data, 8 used echocardiography data, and 1 used both. The CA gold standard was typically defined as a CA diagnosis in an institutional or other database but the requirements for these diagnoses were heterogenous across studies, and many did not distinguish among CA subtypes. AI model development varied considerably, and only 4 studies included external validation. The ability of models to predict CA ranged from 0.71 to 1.00, sensitivity ranged from 16% to 100%, and specificity from 75% to 100%. Only 1 study reported model performance across strata of sex, age, race, and CA type. Persistent challenges to AI adoption include usability, cost, value added, electronic health record/information technology interoperability, patient‐related factors, regulation, and privacy and liability. Published studies on AI for improved identification of CA show favorable performance measures but numerous methodologic and other challenges must be addressed before these tools are more widely adopted.
Primary Cutaneous Anaplastic Large Cell Lymphoma With TCR‐γδ Expression: A Case Series of Eleven Patients of a Rare Immunophenotypic Variant
Erem, Anna Sarah , Mitteldorf, Christina , Pulitzer, Melissa , Rodríguez-Pinilla, Socorro Marıá , Feldman, Andrew L. , Gru, Alejandro A. , Pulitzer, Melissa , Torres-Cabala, Carlos , Feldman, Andrew L , Gru, Alejandro , Kempf, Werner , Torres‐Cabala, Carlos A. , Pileri, Stefano

Mayo Clinic

Journal of Cutaneous Pathology | April 9, 2025 | Volume: 52 | Issue: 7 | Pages: 487-496

10.1111/cup.14809 | PMID 40202044 Get It

ABSTRACTBackgroundPrimary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis (LyP) are indolent CD30‐positive lymphoproliferative disorders that rarely express TCR‐γδ. However, primary cutaneous gamma‐delta T‐cell lymphoma (pcGDTCL), characterized by TCR‐γδ expression on neoplastic cells, is a rare, aggressive cutaneous T‐cell lymphoma with a poor prognosis. Accurate differentiation is essential due to distinct clinical behavior and treatment.MethodsWe identified 11 TCR‐γδ‐positive pcALCL cases from internal and consultation files, verified by two cutaneous lymphoma experts, with clinicopathologic data recorded.ResultsThe median age was 68 years (range 38–95). Most cases presented as a single dermal lesion on the upper extremities. All were ALK‐negative, CD30‐positive (> 90% tumor cells), TCR‐βF1‐negative, and diffusely TCR‐γδ‐positive. CD4−/CD8− (54.5%) and CD4+/CD8− (45.5%) immunophenotypes were observed. CD2 (63.6%) and CD3 (54.5%) were the most common T‐cell antigens. Ulceration, inflammation (both 45.5%), and necrosis (36.4%) were frequent. Angiotropism, angiocentricity, and myxoid stroma appeared in one case; epidermotropism in two. Four of ten tested were DUSP22‐rearranged, and TP63 was negative in all eight tested.ConclusionsMost ALK‐negative TCR‐γδ‐positive pcALCL were CD4−/CD8−, followed by CD4+/CD8−. DUSP22 rearrangement occurred in 40% of cases, similar to reports in typical pcALCL. Its prognosis and the role of DUSP22 are yet to be clarified.
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Lin, Daniel W. , Feldman, Darren R., Aggarwal, Rahul , Drakaki, Alexandra , Eggener, Scott E. , Humphrey, Peter A. , Leuva, Harshraj , Levine, Ellis G., Maughan, Benjamin L. , Reichert, Zachery R. , Rwigema, Jean‐Claude M. , Shah, Sumit, Singla, Nirmish, Sircar, Kanishka , Zhumkhawala, Ali , Sliker, Bailee , Gilligan, Timothy D. , Adra, Nabil , Bagrodia, Aditya , Yamoah, Kosj , Chandrasekar, Thenappan , Costa, Daniel Nobrega da , Drakaki, Alexandra , Emamekhoo, Hamid , Geynisman, Daniel M. , Graham, Laura , Luckenbaugh, Amy N. , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Rais‐Bahrami, Soroush , Saylor, Philip J. , Shah, Ankeet , Shah, Sumit, VanderWeele, David James , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0018 | PMID 40203876 Get It

The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Biermann, J. Sybil, Boles, Sarah G , Brigman, Brian E. , Callan, Alexandra K. , Cranmer, Lee D., Davis, Jessica , Donnelly, Eric D. , Ferguson, Michael J. , Graham, Ann, Groundland, John , Hess, Matthew, Hiniker, Susan M. , Hoover‐Regan, Margo , Jonard, Brandon , Lindskog, Dieter M. , Mayerson, Joel , McGarry, Sean V., Olson, Daniel J. , Rose, Peter S. , Santana, Victor M. , Satcher, Robert L. , Schwartz, Herbert S. , Shulman, Rebecca M. , Wustrack, Rosanna , Yoon, Janet, Hang, Lisa E., Jones, Frankie, Sansone, Nicholas, Lyons, Megan , Hirbe, Angela C. , Ahlawat, Shivani , Bernthal, Nicholas M , Binitie, Odion , Cipriano, Cara A. , Cranmer, Lee D. , Graham, Ann, Hess, Matthew, Hornick, Jason L. , Kuechle, Joseph , Morris, Carol D. , Thorpe, Steven W. , Wilky, Breelyn A , Lyons, Megan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0017 | PMID 40203873 Get It

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Dima, Danai , Afrough, Aimaz , Goel, Utkarsh , Grajales‐Cruz, Ariel , Khouri, Jack , Julian, Kelley , Banerjee, Rahul , Razzo, Beatrice M. , Ferreri, Christopher J. , Martinez, Mariola Alejandra Vazquez, Davis, James A. , Sannareddy, Aishwarya , Raza, Shahzad , Portuguese, Andrew J. , Gaballa, Mahmoud , Rana, Masooma , DeJarnette, Shaun, Gonzalez, Rebecca , Mikkilineni, Lekha , Hosoya, Hitomi , Ouchveridze, Evguenia, Shune, Leyla , Lin, Yi , Sborov, Douglas W. , Anderson, Larry D. , Cowan, Andrew J., Patel, Krina K. , Voorhees, Peter M. , Sidana, Surbhi , Hansen, Doris K., Susanibar-Adaniya, Sandra P. , Grajales-Cruz, Ariel F , Banerjee, Rahul , Vazquez-Martinez, Mariola A , Davis, James A , Portuguese, Andrew J , Rana, Masooma S , Lieberman-Cribbin, Alex , Chen, Anna , Herr, Megan M. , Anwer, Faiz , Sborov, Douglas W , Garfall, Alfred L , Lee, Hans C , Anderson, Larry D , Patel, Krina , Voorhees, Peter , Sidana, Surbhi , Dima, Danai , Raza, Shahzad , Hosoya, Hitomi , Julian, Kelley L , Susanibar-Adaniya, Sandra P , Pasvolsky, Oren , Vazquez‐Martinez, Mariola , Puglianini, Omar Castañeda , Ouchveridze, Evguenia, Kaur, Gurbakhash , Rossi, Adriana , Anwer, Faiz , Richard, Shambavi , Baz, Rachid , Garfall, Alfred L. , Lee, Hans C. , Hansen, Doris K. , Atrash, Shebli

Mayo Clinic

Blood Advances | April 8, 2025 | Volume: 9 | Issue: 14 | Pages: 3408-3417

10.1182/bloodadvances.2025016059 | PMID 40198766 Get It

Abstract Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) <40 mL/min. CrCl <30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.
Perspectives of older adults with memory decline participating in a prolonged nightly fasting (PNF) pilot study: A qualitative exploration
James, Dara , James, Sarah E. , James, Dara L , Ahlich, Erica M. , Maxfield, Molly , Kechter, Afton , Koskan, Alexis M. , Sears, Dorothy D.

Mayo Clinic

Journal of Clinical and Translational Science | April 8, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1017/cts.2025.63 | PMID 40529001 Get It

Abstract Introduction: Cognitive decline and sleep concerns are significant health issues among older adults. Nonpharmacological treatments to address these concerns are needed, particularly for older adults who are more likely to be prescribed multiple medications and experience adverse effects of additional drugs. The aim of the current qualitative study was to understand and document the experiences of older adults with subjective memory decline participating in prolonged nightly fasting (PNF) intervention. Methods: This single-group pilot study was conducted as a fully remote, 8-week, pre/postintervention. Postintervention, 16 participants (≥65 years) participated in semistructured qualitative exit interviews about their experiences with the PNF intervention. Interviews lasted approximately 20–30 minutes, were conducted by trained study staff, and then analyzed by the team to understand relevant themes. Results: Two major themes that emerged from the data were engagement with and perceived effects of the PNF intervention. Within these two themes, nine subthemes emerged: accountability; use of days off; feasibility; intervention tools; behavioral strategies; timing/routine; awareness; self-efficacy; and perceived health-related outcomes. Overall, interviews suggested strong engagement with the PNF intervention as well as a number of positive perceived effects of the intervention. Conclusions: These findings contribute to a broad field of intermittent fasting by exploring and understanding the direct experiences of older adults participating in PNF. Some participants identified challenges of participation, yet this qualitative approach can guide future PNF implementation with older adults. Notably, responses support the quantitative data suggesting that PNF is a feasible and acceptable intervention for older adults.
Nerve Biopsy is More Sensitive Than Fat Aspirate or Skin Biopsy for Amyloid Tissue Diagnosis in Symptomatic ATTRv Peripheral Neuropathy (P12-11.009)
Panrudkevich, Alex , Dyck, P. James B. , Shouman, Kamal , Berini, Sarah E. , Jacobi, Jackie, Engelstad, JaNean , Grogan, Martha , Khoury, Julie, Mauricio, Elizabeth A. , Jones, Felipe J.S. , Klein, Christopher J. , Lamb, Christopher, Jacobi, Jackie, Staff, Nathan P. , Dubey, Divyanshu , Dispenzieri, Angela , Mauricio, Elizabeth A. , Mauermann, Michelle L. , Pinto, Marcus Vinícius

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211212 Get It

Person-Centered Care and Trial Design for Progressive Supranuclear Palsy: A Collaborative Project of AFTD and CurePSP (P8-3.020)
Dodge, Shana , Shurer, Jessica , Ali, Farwa , Lin, Chi-Ying , Rojas-Martinez, Julio, Wang, Catherine, Wills, Anne‐Marie , Diaz, Kristophe , Irwin, David J. , Kremen, Sarah , VandeVrede, Lawren , Dacks, Penny A.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210658 Get It

Self-Reported Cognitive Complaints and Work Productivity in Participants With Narcolepsy or Idiopathic Hypersomnia After Low-Sodium Oxybate Treatment: Results From the Phase 4 DUET Study (P8-4.002)
Schneider, Logan , Ruoff, Chad , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Kirby, M. Todd, Akerman, Sarah , Alexander, Jessica, Cairns, Alyssa , Ruoff, Chad M , Plante, David T.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211176 Get It

Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia: Top-line Results From the Phase 4 DUET Study (P10-2.008)
Schneider, Logan , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Kirby, M. Todd, Akerman, Sarah , Alexander, Jessica, Ruoff, Chad , Cairns, Alyssa , Ruoff, Chad M , Plante, David T.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211853 Get It